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Gastrointestinal stromal tumours (GIST) are deﬁned as KIT
(CD117, stem cell factor receptor) positive mesenchymal spindle
cell neoplasms accounting for 3% of all gastrointestinal neoplasms.
Out of them, only 5% are found in the colon. The diagnosis of the
GIST is made on histopathological features. The deﬁnitive diagnosis
of a GIST has become more precise in the recent years with the
introduction of routine immunohistochemistry to identify positive
expression of the tyrosine kinase Kit receptor (CD117) and negative
expression for desmin and S-100, as would be consistent with the
cell of origin being the interstitial cell of Cajal. Only in 5% of cases
histologically suspected GIST are CD117 negative. Here, we arearwal).
Elsevier Ltd on behalf of Surgical Areporting a case of malignant CD 117 negative colonic GIST in
a young patient which is quite rare.
2. Case report
A 21 years old girl presented with complaints of pain and mass
on right side of abdomen for three months. Colonoscopy was done
which showed a growth in hepatic ﬂexure of colon [Fig. 1]. CT scan
of the patient was done [Fig. 2]. Patient was planned for exploratory
laparotomy and abdomen was opened from midline. Per-opera-
tively there was a mass in ascending colon and another mass
(lymph node metastasis) in the mesocolon. Right hemicolectomy
was done with no touch technique and illeotransverse anastomosis
was done [Fig. 3]. The post-operative course was uneventful and
the patient is still on follow up and is on Imatinib drug therapy.
On gross examination right hemicolectomy specimen showed
an exophytic polypoidal growth with a narrow base arising from
the mucosa in the region of ascending colon. The growth measured
4  4  3 cm and had an ulcerated nodular surface. Cut surface
showed a nodular lobulated appearance with varying size nodules,
soft to feel and showed few tiny haemorrhagic areas. On the serosal
aspect in the region of caecum and colon there were multiple
lobulated lesions largest measuring 9  5  4 cm, second largest
6 4 4 cmwhichwere capsulated. The cut surface was soft, grey-
white and showed haemorrhagic areas. No necrotic areas were seen
on gross. These appeared to be matted lymph nodes. In addition 13
other discrete lymph nodes identiﬁed from the colonic and caecal
region and 10 lymph nodes identiﬁed from ileal mesentery.
On microscopic examination [Fig. 4] the tumour tissue showed
multicentric pushing borders and is composed of two types of cells.
One is oval to spindle and other is plump epitheloid variety. Spindle
cells are forming interlacing bundles and clusters, while plump
cells are arranged diffusely. Tumour cells exhibit mild to moderate
anisocytosis, hyperchromasia and mild pleomorphism. Increasedssociates Ltd.
Fig. 1. Colonoscopic Image of Tumour.
Fig. 3. Gross image of resected specimen.
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in the muscularis propria and also in the serosa. All matted lymph
nodes along with 12 out of 23 lymph nodes showed extensive
tumour metastasis. Resection margins were free of tumour tissue.
Immunohistochemistry was done and the tissue was negative
for CD117/C-KIT, CD34, Smooth Muscle Actin, S-100, Calponin,
Desmin, CK LMW Squamous, but was positive for Vimentin.
Morphology and IHC favoured diagnosis of Malignant Gastro-
intestinal Stromal Tumour (C-KIT, CD34 and S-100 e Negative).Fig. 2. CECT image of tumour.3. Discussion
Gastrointestinal stromal tumours (GISTs) are rare tumours that
account for less than 3% of all gastrointestinal neoplasms.1,2 The
majority - approximately 60e70% - of gastrointestinal GISTs are
found in the stomach, 25e35% in the small intestine, about 5% in
the colon, rectum and appendix, and 3% in the oesophagus.2 The
precise incidence of GIST remains unknown as the diagnosis has
been modiﬁed recently, but is estimated at approximately four per
million per year.2 The incidence appears to be uniform across all
geographic and ethnic background, and men and women are
equally affected. In the majority of patients, GIST is commonly
diagnosed in the ﬁfth to seventh decades; it is unusual to ﬁnd GIST
in patients under the age of 40.2 The most common clinical mani-
festations of GIST are gastrointestinal bleeding and abdominal pain,
followed by signs and symptoms of obstruction, abdominal mass
and metastatic disease.3 Colorectal GISTs are relatively rare,
frequency being reported at approximately 5%.4 Moreover, the
pathobiological features of malignant GISTs of the colon remain
unclear.5,6 The cell of origin for GIST is thought to be the interstitial
cell of Cajal.7 Though GIST may be identiﬁed by light microscopy,
pathologists commonly employ a panel of immunohistochemical
markers to conﬁrm the morphological impression including
anti-CD34, smooth muscle actin, desmin, S100, and CD-117.
Immunoreactivity for KIT distinguishes GISTs from true leiomyo-
mas, leiomyosarcomas, schwannomas, and neuroﬁbromas.8e11
Although the demonstration of c-kit (CD117) immunoreactivityFig. 4. Microscopic image of tumour.
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5% of histologically suspected GIST are CD117 negative.4,12,13
However, in CD-117 negative cases, it becomes difﬁcult to diag-
nose GIST. Approximately 70% of GISTs are positive for CD34,
20e30% are positive for smooth muscle actin (SMA), 10% are posi-
tive for S100 protein and <5% are positive for desmin.4 The
expression of CD34 and SMA is often reciprocal. Between 10% and
30% of GISTs may behave in a malignant manner.14 Fletcher et al.
(2002) proposed an approach for assessing potential risk of
aggressive behaviour in a GIST based on tumour size and mitotic
count.15 Bucher et al. (2004) proposed a classiﬁcation to identify
malignant potential based on tumour size, mitotic index and the
presence of necrosis, inﬁltration of adjacent structures and pres-
ence of lymph node invasion ormetastases.16 The importance of the
site of the primary GIST has been debated; some authors have
found that prognosis is signiﬁcantly inﬂuenced by site and others
have not.17 However, none of these factors taken independently is
predictive of the malignant potential of a GIST, with the exception
of metastatic disease at ﬁrst presentation.15e20
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